- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2026, CIRCULAR DATED 31 ... | 4 | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2026, CIRCULAR DATED 31 ... | 2 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 30.07. | EXTRAWELL PHAR (00858): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 AUGUST 2026 AT 11:00 A.M. | - | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL ... | - | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): ANNUAL REPORT 2026 | 1 | HKEx | ||
| 30.06. | EXTRAWELL PHAR (00858): ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026 | 1 | HKEx | ||
| 23.06. | EXTRAWELL PHAR (00858): PROFIT WARNING | - | HKEx | ||
| 16.06. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 2 | HKEx | ||
| 29.05. | EXTRAWELL PHAR (00858): (1) FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) ... | - | HKEx | ||
| 14.04. | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 27.03. | EXTRAWELL PHAR (00858): MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS | - | HKEx | ||
| 17.03. | EXTRAWELL PHAR (00858): COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION ... | - | HKEx | ||
| 27.02. | EXTRAWELL PHAR (00858): (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN ... | - | HKEx |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 54,54 | +2,52 % | Ionis Pharmaceuticals, Inc.: Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress... ► Artikel lesen | |
| CSPC PHARMA | 1,038 | +0,89 % | Laufende Fusionskontrollverfahren: 1. AstraZeneca plc, Cambridge/UK; 2. CSPC Pharmaceutical Group Limited, Shijiazhuang, Hebei/China; Erwerb gemeinsamer Kontrolle über ein neu zu gründendes Gemeinschaftsunternehmen (JV) in Shijiazhuang, Hebei/China | Datum der Anmeldung:13.08.2026Aktenzeichen:B3-92/26Unternehmen:1. AstraZeneca plc, Cambridge/UK; 2. CSPC Pharmaceutical Group Limited, Shijiazhuang, Hebei/China; Erwerb gemeinsamer Kontrolle über ein... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 12,900 | +4,88 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 445,00 | +1,23 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ACADIA PHARMACEUTICALS | 25,190 | -0,87 % | Acadia Pharmaceuticals Inc.: Europäische Kommission erteilt Zulassung für DAYBU (Trofinetid) als erste und einzige Therapie für neurobehaviorale Symptome des Rett-Syndroms in der Europäischen Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hat heute bekannt gegeben, dass die Europäische Kommission (EK) die Marktzulassung für DAYBU (Trofinetid) zur Behandlung neurobehavioraler Symptome des Rett-Syndroms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,520 | +1,73 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SAVARA | 4,670 | -2,16 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 3,300 | +1,23 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,350 | +12,50 % | Biodexa Pharmaceuticals PLC: Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP | August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa"... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,026 | -1,92 % | Neurizon Therapeutics Ltd Full Year Loss Declines | ||
| CIPHER PHARMACEUTICALS | 8,700 | 0,00 % | Cipher Pharmaceuticals verfehlt Umsatzprognose für Q2 2026, Aktie legt dennoch zu | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - 8-K, Current Report | ||
| VASO | - | - | Vaso Corporation Announces Financial Results for Second Quarter of 2026 | PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive... ► Artikel lesen |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.